China Pharma Holdings Inc

China Pharma Holdings Inc maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The company holds total assets of $30.99 million against total liabilities of $8.26 million, leaving total equity of $22.74 million. Liquidity is constrained, with cash and equivalents standing at only $0.35 million, which is significantly lower than the total liabilities. The current ratio is not explicitly provided, but the low cash balance relative to liabilities suggests tight liquidity conditions. The market capitalization is $10.28 million, trading at a price-to-book ratio of 0.45, indicating the market values the company at less than half its book value.

Profitability metrics are negative across all key measures. The company reported a net loss of $3.19 million on revenue of $4.14 million, resulting in a return on equity of -14.02% and a return on assets of -10.28%. The gross profit was negative at -$0.13 million, indicating that the cost of goods sold exceeded revenue, a critical operational inefficiency. The operating income was -$3.24 million, further highlighting the lack of operational profitability. These figures are significantly below typical industry medians for profitable pharmaceutical companies, suggesting the company is in a development or turnaround phase rather than a mature growth stage.

Revenue concentration and segment data are not explicitly detailed in the provided financial snapshot, but the company's reliance on specific suppliers is notable. Two suppliers accounted for 26.6% and 26.3% of raw material purchases, indicating a moderate concentration risk in the supply chain. This dependency could pose operational risks if either supplier faces disruptions. Geographic exposure is not detailed in the available data, but the company's listing on the London Stock Exchange (CPHI.K) suggests international investor exposure.

Growth trajectory data is limited to the latest period, with revenue of $4.14 million. Without historical period data, it is difficult to assess the growth trend. However, the negative gross profit and operating income suggest that the company is not currently growing profitably. The lack of positive cash flow from operations, with operating cash flow at $0.15 million, further indicates that the company is not generating sufficient cash from its core business to sustain operations without external funding or asset sales.

Risk factors include low liquidity and potential supply chain concentration. The company has no immediate filing-based liquidity or dilution flags, but the low cash balance relative to liabilities is a concern. The negative gross profit is a significant red flag, indicating that the company's core business model is not currently viable. The reliance on two major suppliers for over 50% of raw material purchases adds to the operational risk.

Recent events include a sector contamination re-analysis via the sector classification direct path, which may have impacted the company's classification or market perception. There are no other significant news events or filing observations reported in the available data. The company's IR observations highlight the supplier concentration, which is a key risk factor to monitor.

China Pharma Holdings Inc (CPHI.K) has undergone a comprehensive revision of its analytical profile, with significant updates to its business summary, key takeaways, and overall conclusion. These modifications, sourced from the ha_light_thesis, indicate a substantial shift in the underlying narrative and strategic assessment of the company, as evidenced by the low similarity scores between the old and new analyses. The most notable data addition is the introduction of a specific market share figure, which was previously unrecorded. The company's market share is now quantified at approximately 2.56e-08, providing a concrete metric for its position within the broader market landscape. This new data point fills a previous gap in the produced data, allowing for more precise comparative analysis. Despite these updates to the analytical framework and data points, the overall assessment notes that there is no material change versus the prior analysis when excluding schema-expansion fields. This suggests that while the presentation and specific metrics have been refined, the fundamental outlook or core financial health of the company remains consistent with previous evaluations. The company's profile continues to reflect a limited presence in terms of analyst coverage and index membership, with zero analysts and zero index memberships recorded. Additionally, the officer count remains at zero, and there is only one top holder identified, highlighting the company's niche status and limited public scrutiny in the current financial ecosystem.

Net income improved 32.7% year-over-year, indicating a significant reduction in losses compared to the prior fiscal period.

Operating income increased 29.4% year-over-year, suggesting improved operational efficiency despite continued negative margins relative to peers.

Free cash flow improved 27.6% year-over-year, demonstrating a positive trend in cash generation capabilities.

Long-term debt decreased from $12.4 million in 2008 to $3.4 million, showing a consistent deleveraging trajectory.

Dilution risk is assessed as low, providing some stability for existing shareholders regarding equity structure.

Credit risk is flagged as high, indicating significant concerns regarding the company's ability to meet financial obligations.

Current ratio of 0.32 suggests severe liquidity constraints, as current assets cover only a fraction of current liabilities.

Revenue $1.2M, +8,1% YoY; Operating income −0,3% YoY.

• ▍Revenue $1.2M, +8,1% YoY
• ▍Operating income −0,3% YoY
• ▍Net income +0,2% YoY
• ▍Free cash flow +37,6% YoY
• ▍Net margin -99.7%

Revenue $756.2k, −31,3% YoY; Operating income +42,1% YoY.

• ▍Revenue $756.2k, −31,3% YoY
• ▍Operating income +42,1% YoY
• ▍Net income +41,7% YoY
• ▍Free cash flow +18,4% YoY
• ▍Net margin -86.1%

Revenue $1.0M, +10,9% YoY; Operating income +53,1% YoY.

• ▍Revenue $1.0M, +10,9% YoY
• ▍Operating income +53,1% YoY
• ▍Net income +63,3% YoY
• ▍Free cash flow +66,9% YoY
• ▍Net margin -51.5%

Revenue $1.1M; Operating income -$758.6k.

• ▍Revenue $1.1M
• ▍Operating income -$758.6k
• ▍Net margin -69.1%

Revenue $1.1M; Operating income -$1.2M.

• ▍Revenue $1.1M
• ▍Operating income -$1.2M
• ▍Net margin -108.0%

Revenue $1.1M; Operating income -$1.1M.

• ▍Revenue $1.1M
• ▍Operating income -$1.1M
• ▍Net margin -101.6%

Revenue $924.9k; Operating income -$1.4M.

• ▍Revenue $924.9k
• ▍Operating income -$1.4M
• ▍Net margin -155.5%

Revenue $4.5M, −35,4% YoY; Operating income −66,8% YoY.

• ▍Revenue $4.5M, −35,4% YoY
• ▍Operating income −66,8% YoY
• ▍Net income −53,8% YoY
• ▍Free cash flow −615,8% YoY
• ▍Net margin -104.6%

Revenue $7.0M, −13,5% YoY; Operating income +22,5% YoY.

• ▍Revenue $7.0M, −13,5% YoY
• ▍Operating income +22,5% YoY
• ▍Net income +22,5% YoY
• ▍Free cash flow +79,9% YoY
• ▍Net margin -43.9%

Revenue $8.1M, −15,9% YoY; Operating income −24,1% YoY.

• ▍Revenue $8.1M, −15,9% YoY
• ▍Operating income −24,1% YoY
• ▍Net income −16,9% YoY
• ▍Free cash flow −123,3% YoY
• ▍Net margin -49.0%

Revenue $9.6M; Operating income -$2.9M.

• ▍Revenue $9.6M
• ▍Operating income -$2.9M
• ▍Net margin -35.3%